working
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No, I do not think so
We need the company to show something "attractive" to the market,
It only tells us about the money generated by the industry,
But does it have something to offer the industry?
when we prove it WE WILL FLY
I still think the same,
we do not know, therefore speculation
There are only two reliable sources,
official presentations and transfer agent
I have only commented on the facts,
here it has been said how much is diluted daily without any knowledge,
I don't speculate about the future,
I don't know what will happen in the future,
I think nobody here knows
the reality is in the numbers, the reports ...
everything else ... interested noise
10Q: Outstanding share count went from 202,631,923 to 212,369,124 between 6/30/19 and 9/30/19 or 9,737,201 shares total.
Where is the mass dilution since the meeting and increase?
no dilution,
the numbers are here,
the rest is only speculation
good shopping on IPIX
ENDP 4,82 VOL 14 mill
today yes, 0.10
Why do you copy the publication of another board?
they're selling...?
who? 18.001 vol
LOL
NEWS IPIX:
Innovation Pharmaceuticals Highlights Preclinical Data by Independent Cancer Researchers Supporting p53 Drug Candidate Kevetrin’s Potential in Treating Acute Myeloid Leukemia
BEVERLY, MA – October 28, 2019 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to highlight preclinical data by independent cancer researchers supporting the therapeutic potential of Kevetrin, the Company’s novel p53-modulating anti-cancer drug candidate, in treating Acute Myeloid Leukemia (AML).
Building on Kevetrin data in AML presented at the 2017 European Hematology Association (EHA) Annual Meeting, a group of independent cancer researchers recently presented additional data at the June 2019 EHA Annual Meeting, and at the October 2019 Italian Society of Hematology Annual Meeting.
Results showed that Kevetrin alters cellular metabolism and several key genes, including TP53 and MYC, both of which when dysfunctional are implicated in many types of cancers, including AML.
The researchers' conclusion as presented at the June 2019 EHA Annual Meeting:
Our results show Kevetrin alters several key genes and cellular metabolism. Along with cellular data, this study could provide a rationale for an experimental trial in AML patients, especially those carrying TP53 mutation who actually have very few therapeutic options.
A related scientific article remains under review for publication. The paper details Kevetrin’s treatment potential in AML by targeting p53 and several key leukemia-related genes.
The continued publication flow of encouraging studies related to Kevetrin’s potential in AML is particularly promising. AML accounts for almost one-third of all leukemias worldwide and has a 5-year survival rate of only 25 percent. Pre-clinical research and academic literature also support Kevetrin’s potential in combination with cancer immunotherapies.
Kevetrin was shown to be well-tolerated in a completed Phase 1 clinical trial in Advanced Solid Tumors, with a separate Phase 2a clinical trial in late-stage Ovarian Cancer showing intra-tumor p53 modulation. P53 is the most studied gene of all time, eliciting significant private and public investment—e.g., see Aprea Therapeutics, PMV Pharma, Aileron Therapeutics—given an approved p53 drug would likely have a large impact in fighting many types of cancer. Next steps within the Innovation Pharmaceuticals cancer program is to complete the necessary remaining bridging toxicology work toward developing Kevetrin in oral formulation, both to leverage its pharmacokinetics (PK) profile and provide a more patient-friendly mode of administration.
Linked below is a blog post on the Company’s website providing the scientific abstracts cited above.
“2019 European Hematology Association and Italian Society of Hematology Abstracts on Kevetrin’s Therapeutic Potential in Acute Myeloid Leukemia”
http://www.ipharminc.com/new-blog/2019/10/28/2019-european-hematology-association-and-italian-society-of-hematology-abstracts-on-kevetrins-therapeutic-potential-in-acute-myeloid-leukemia
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
pumping? very little effective
more than a year 0 BID
300 mill, 40 mill .... who knows.
that will depend exclusively on the PPS,
"average down"
careful with this,
if the PPS goes up ... well
but if the PPS keeps falling,
you will always have a losing position,
Will your loss percentage be lower? YES, but with more money invested,
I Agree, and they have more information than us ...
No one knows what the schedule is for any potential deal,
nobody knows if it will be fast or slow,
they all know the same as you or me: absolutely nothing,
Seeing the volume, no dilution here, maybe an interested company requested shares to be purchase as part of a deal ...
News Ipix: Notice of Effectiveness (effect)https://www.otcmarkets.com/filing/html?id=13694142&guid=H37SUa40axgu2th
"As of September 23, 2019, there were 211.6 million shares of our Class A common stock outstanding and 909,090 shares of Class B common stock outstanding."
Volume 100 tit
nobody, including you, will sell for $ 0.03,
in many cases, including you, bought in dollars,
patiently waiting for $ 0.115
and prepared to buy their titles
we have exceeded yesterday's volume
A little humor. LOL
"Let's see what you have to say if they pull a R/S after all the dilution"
Guess the future?
Why? A/S 600.000.000 but O/S is 213.000.000
"mini" shopping
IPIX 0.11$
VOL 85.706
nothing at all for OTC markets
213 mill O/S is nothing
300 mill idem
The market will be able to price, with its unsustainable exaggerations
IPIX reached $ 5 in December 2014
that we now have 600,000,000?
in the OTC world is not an exaggerated AS
when "someone" decides that PPS has to go up,
will go up and the AS will not matter
We just need some volume,
ASK is very thin,
and we will have it soon ...
0.12 OUT, 0.12 x 0.1295
IPIXX
hitting $ 0.12, path of 0.14
IPIX
Pump & DUmp with 89.116 volume?. LOL
it is incredible what can be written here
I'm buying some more too,
not rush,
risk reward on our side
150M to 14M shareholder vote FOR. That tells us the FACT that over 90% of $IPIX shares are strongly held and it is doubtful that this 90%+ will sell their shares cheaply.
OTCQB Member Since 09/2019
Verified Profile 09/2019
Transfer Agent Verified
https://www.otcmarkets.com/stock/IPIX/security
IPIX